Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 2
1(50.0%)
2Total
N/A(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01146782Not ApplicableCompleted

Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea

Role: lead

NCT01634074Unknown

Reiterative Development and Evaluation Study of OSA Therapy System

Role: lead

NCT01683721Unknown

Post-Market Observational Study of the WINX Sleep Therapy for the Treatment of Obstructive Sleep Apnea (OSA)

Role: lead

NCT01476917Phase 2Completed

The ATLAST Long-Term Study

Role: lead

All 4 trials loaded